Assessment of Double-Blindness at the Conclusion of the Beta-Blocker Heart Attack Trial
Byington, Robert P.
Curb, J. David
Mattson, Margaret E.
JAMA. 1985 Mar 22/29; 253(12): 1733-1736.
At the conclusion of the Beta-Blocker Heart Attack Trial (BHAT), a major research project sponsored by the National Heart, Lung, and Blood Institute, investigators conducted a survey to assess the effectiveness of the trial's double-blind design. Patients, physicians, and coordinators were asked to guess the treatment group assignment of each subject. Patients receiving the drug, propanolol, were better able to identify their assignment than those receiving a placebo. Clinic personnel were better able than the patients to differentiate between the two groups, probably due to their monitoring of patients' heart rates. The BHAT researchers concluded that, although double-blindness was not completely achieved, this fact did not influence the conduct of the trial, as no group differences in drug and visit compliance or in the use of concomitant therapy were found. (KIE abstract)
Showing items related by title, author, creator and subject.
Unknown author (United States. National Heart, Lung, and Blood Institute. Beta-Blocker Heart Attack Study Group, 1981-11-06)The National Heart, Lung, and Blood Institute has taken the unusual step of prematurely ending one of its major clinical trials, the Beta-Blocker Heart Attack Trial (BHAT), on the advice of its Policy and Data Monitoring Board. ...